These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28048942)

  • 1. Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models.
    Burns KE; Hensley H; Robinson MK; Thévenin D
    Mol Pharm; 2017 Feb; 14(2):415-422. PubMed ID: 28048942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates.
    Burns KE; Robinson MK; Thévenin D
    Mol Pharm; 2015 Apr; 12(4):1250-8. PubMed ID: 25741818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
    Hingorani DV; Doan MK; Camargo MF; Aguilera J; Song SM; Pizzo D; Scanderbeg DJ; Cohen EEW; Lowy AM; Adams SR; Advani SJ
    Mol Cancer Ther; 2020 Jan; 19(1):157-167. PubMed ID: 31597712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.
    Capone E; Lamolinara A; D'Agostino D; Rossi C; De Laurenzi V; Iezzi M; Iacobelli S; Sala G
    J Control Release; 2018 May; 277():48-56. PubMed ID: 29550398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis.
    Currier NV; Ackerman SE; Kintzing JR; Chen R; Filsinger Interrante M; Steiner A; Sato AK; Cochran JR
    Mol Cancer Ther; 2016 Jun; 15(6):1291-300. PubMed ID: 27197305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
    Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
    Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
    Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
    Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.
    Powell Gray B; Kelly L; Ahrens DP; Barry AP; Kratschmer C; Levy M; Sullenger BA
    Proc Natl Acad Sci U S A; 2018 May; 115(18):4761-4766. PubMed ID: 29666232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
    Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
    Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
    D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
    Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
    Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
    Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
    Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.
    Oflazoglu E; Stone IJ; Gordon K; Wood CG; Repasky EA; Grewal IS; Law CL; Gerber HP
    Clin Cancer Res; 2008 Oct; 14(19):6171-80. PubMed ID: 18809969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
    Akaiwa M; Dugal-Tessier J; Mendelsohn BA
    Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models.
    Moquist PN; Bovee TD; Waight AB; Mitchell JA; Miyamoto JB; Mason ML; Emmerton KK; Stevens N; Balasubramanian C; Simmons JK; Lyon RP; Senter PD; Doronina SO
    Mol Cancer Ther; 2021 Feb; 20(2):320-328. PubMed ID: 33288628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.
    McDonagh CF; Kim KM; Turcott E; Brown LL; Westendorf L; Feist T; Sussman D; Stone I; Anderson M; Miyamoto J; Lyon R; Alley SC; Gerber HP; Carter PJ
    Mol Cancer Ther; 2008 Sep; 7(9):2913-23. PubMed ID: 18790772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.